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Colonic Dendritic Cells, Intestinal Inflammation,
and T Cell-Mediated Bone Destruction
Are Modulated by Recombinant Osteoprotegerin
extended as a result of the identification of novel mem-
bers linking lymphoid cells with bone morphogenesis.
The TNF family molecule RANKL and its receptor RANK
are key regulators of bone remodeling and are essential
for the development and activation of bone-resorbing
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Introduction Although the function of RANKL/RANK interactions out-
side the bone and immune system is less well defined,
Members of the tumor necrosis (TNF) superfamily of recent studies have identified a role in the formation of
ligands and cell-surface-receptors regulate a variety of lactating mammary glands (Theill et al., 2002).
cellular functions ranging from proliferation and differen- Collectively, these findings suggest that abnormalities
tiation to inflammation, cell survival, and death (Fu and in the regulation of RANKL/RANK interactions might be
Chaplin, 1999; Grewal and Flavell, 1998; Locksley et al., a common feature of a variety of disorders in addition
2001). The role of this superfamily has recently been to bone loss that are characterized by chronic or uncon-
trolled T cell activation. To investigate this further we
have examined Interleukin 2-deficient (IL2/) mice that*Correspondence: s.r.carding@leeds.ac.uk
spontaneously develop an autoimmune disorder char-8Present address: ANZAC Research Institute, Concord Hospital,
Concord, NSW, Australia. acterized by hyperactivation of CD4 T cells leading to
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multiorgan inflammation, production of autoantibodies ing dynamic histomorphometry identified a trend toward
increased bone formation in 4 week IL2/ animals com-of various specificities (Schimpl et al., 2002), anemia,
and bone marrow failure (Reya et al., 1998). In particular, pared to controls (Figure 1F). This was supported by a
significantly raised bone-specific alkaline phosphatasethese animals develop an inflammatory bowel disorder
that resembles ulcerative colitis, is T cell mediated, and level in the serum of these animals when compared to
control littermates (Figure 1G, p  0.001). Serum bone-is triggered by commensal gut bacteria (Contractor et
al., 1998; Sadlack et al., 1993). Here we report that IL2/ specific alkaline phosphatase levels had however de-
clined to normal levels by 7 and 9 weeks of age. Mea-mice develop a profound osteopenia caused by T cells
through increased RANKL production and that this loss sures of bone formation were significantly decreased at
7 weeks of age (Figure 1F, p  0.01) in IL2/ miceof bone mineral density compared to littermate controls
can be blocked by Fc-OPG treatment. We also present compared to controls. Mineral apposition rates were
lower in 7- and 9-week-old IL2/ animals reaching sig-evidence that, in contrast to previous reports (Kong et
al., 1999a), Fc-OPG administration is effective at treating nificance at 9 weeks (p  0.017, data not shown). Tra-
becular thickness in IL2/ animals decreased betweenlocal inflammation and reducing the severity of T cell-
mediated colitis and that this action is mediated by the 4 and 7 weeks, although this was nonsignificant (p 
0.068), and remained unchanged at 9 weeks of age de-effects of Fc-OPG on colonic DC survival in vivo.
spite continuing indications of osteoblastic activity.
Over the same time course trabecular thickness in con-Results
trol animals increased significantly (p  0.029, data not
shown). Cumulatively this data indicated that both re-IL2/ Mice Develop Pronounced Osteopenia
duced bone formation and increased osteoclast num-Compared to their wild-type (IL2/) and heterozygote
bers contribute to the osteopenia in IL2/ mice.(IL2/) littermates, IL2/ mice developed osteopenia
consistent with abnormalities in bone homeostasis. To
investigate the underlying causes of this phenomenon IL2/ T Cells Mediate Bone Disease In Vivo
We have previously shown that IL2/ mice have in-we undertook detailed analysis of bone physiology in
IL2/ mice using established histomorphometric tech- creased numbers of activated T cells that infiltrate multi-
ple organs including the bone marrow (Reya et al., 1998).niques. As T cells are involved in regulating bone physi-
ology and in the pathogenesis of bone disease, we de- Since activated T cells have been shown to regulate
bone loss (Kong et al., 1999a), we assessed whethertermined whether activated T cells and the RANKL/
RANK/OPG system contribute to abnormal bone ho- bone disease in IL2/ mice was T cell mediated. Two
approaches were taken. In the first, bone disease wasmeostasis as well as the multiorgan inflammation that
is a distinguishing feature of the immunopathology seen assessed in mice deficient in  T cells and IL2 produc-
tion (C57BL/6 IL2/  TCR/) at 9 weeks of age. Inin IL2/ mice.
Comparative radiographic analysis of the femora and the second approach, splenic T cells (94% CD3) from
IL2/ or IL2/ littermate mice were adoptively trans-tibia of IL2/ and IL2/ mice kept in specific pathogen
free (SPF) conditions clearly showed generalized os- ferred into lymphocyte-deficient C57BL/6-Rag1/ mice
and the bone phenotype assessed 6–8 weeks after theteopenia and cortical bone thinning in IL2/ mice when
compared to control littermates, which was evident by cell graft.
C57BL/6 IL2/  TCR/ animals showed no evi-7 weeks of age (Figure 1B). Histology revealed extensive
reductions in both cortical and trabecular bone below dence of reduced bone volume when compared to con-
trol animals (Table 1). These mice were maintained forthe growth plate and in the epiphysis of both the femur
and tibia of IL2/ mice (Figures 1A and 1C). Quantitative up to 6 months, during which time they showed no evi-
dence of bone loss when assessed by either densitomet-bone histomorphometric analysis (Figure 1E) further re-
vealed a progressive decrease in trabecular bone vol- ric or histomorphometric techniques and compared to
control animals. In comparison to T cell-sufficient IL2/ume in IL2/ animals relative to IL2/ and IL2/ lit-
termates (femur and tibia p  0.001) and dual emission mice that were too sick to mate, T cell-deficient IL2/
mice also remained healthy and able to breed. Of note,X-ray absorptiometry (DXA) scanning confirmed these
results with a similar decrease of bone mineral density C57BL/6 IL2/  TCR/ animals had significantly in-
creased BMD (p  0.035), reduced serum RANKL levels(BMD) in the IL2/ group compared to controls (9 week
femur and tibia p  0.001). No significant differences in (p  0.002), and reduced RANKL mRNA expression in
the bone marrow (data not shown) compared to C57BL/6trabecular bone volume or BMD between IL2/ and
IL2/ mice were detected at any time point (Table 1) IL2/ control mice. Similar although nonsignificant in-
creases in BMD compared to wild-type littermates wereconsistent with no IL2 gene dosage effect on the devel-
opment of bone disease. These results suggested ab- also seen in Rag1/ mice (M.J.P., unpublished data),
consistent with the involvement of  T cells in normalnormalities of bone development and osteoblast/osteo-
clast homeostasis in IL2/ mice. bone homeostasis. The transfer of IL2/ T cells into
Rag1/ mice reproduced the IL2-deficiency syndromeConsistent with this interpretation were the increased
numbers of osteoclasts present on the trabecular bone 6–8 weeks postinoculation and was associated with
bone disease alongside splenomegaly and colitis, whichof IL2/ mice at 7 weeks of age (p  0.041, Figure
1D) and abnormalities of bone formation and osteoblast are part of the generalized autoimmune condition found
in IL2/ animals (Table 1 and data not shown). A signifi-activity demonstrated using dynamic histomorphometry
and serum bone-specific alkaline phosphatase levels cant decrease in BMD (femur p  0.0013, Figure 2A;
tibia p  0.017, not shown) and trabecular bone volume(Figures 1F and 1G). Assessment of bone formation us-
Osteopenia and Colitis in IL2-Deficient Mice
851
Figure 1. Bone Homeostasis in IL2/ Mice
Femora and tibia from IL2/ (/), IL2/ (/), and IL2/ (/) mice at 4, 7, and 9 weeks of age were analyzed by radiography (B) and
histomorphometry for measurements of overall bone appearance (A and C) and trabecular bone area (E) as described in the Experimental
Procedures. Sections of bone were also TRAP stained (A and C) to determine osteoclast numbers (D). IL2/ mice had significantly less
trabecular bone (A) compared to either IL2/ or IL2/ mice (4w p  0.002; 7 & 9w p  0.001) and significantly greater numbers of osteoclasts
(p  0.041) at 7w (D). Bone formation rates in IL2/ animals as assessed by bone dynamic histomorphometry appeared slightly raised at 4
weeks of age when compared to littermate controls (p  n/s) but was significantly reduced in IL2/ animals at 7 weeks of age (F, p  0.01).
Serum bone-specific (B/S) alkaline phosphatase levels were raised (p  0.001) in IL2/ animals at 4 weeks but had dropped by 7 and 9
weeks of age (G). DLS/BS  double labeled surface/bone surface. The results shown are representative of those obtained from four to six
mice of each genotype and age.
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Table 1. Bone Density Analysis
BMD (mg/cm2)
Genotype Age (Weeks) n Femora (F) Tibia (T)
IL2/ 4 8 35.5 	 2.4 36.1 	 1.0
IL2/ 4 9 37.5 	 1.6 32.7 	 1.2
IL2/ 4 10 31.7 	 1.3a 29.6 	 0.9a
IL2/ 7 16 50.4 	 2.5 43.1 	 1.6
IL2/ 7 9 54.6 	 1.8 42.9 	 1.2
IL2/ 7 11 40.8 	 1.9b 32.4 	 1.5b
IL2/ 9 15 60.1 	 1.1 48.0 	 4.6
IL2/ 9 6 65.0 	 3.8 50.5 	 0.7
IL2/ 9 9 42.5 	 1.7c 35.0 	 1.2c
TCR//IL2/ 9 6 65.3 	 1.8 46.0 	 0.6
TCR//IL2/ 9 12 64.3 	 1.5 46.0 	 1.1
Rag1/  IL2/ CD4 T Cells 14 6 74.0 	 2.2 49.6 	 1.8
Rag1/  IL2/ CD4 T Cells 14 6 57.5 	 2.9d 44.0 	 1.2d
Rag1/ 14 3 68.0 	 1.2 48.7 	 1.7
OPG Rx IL2/ 7 12 59.4 	 2.3e 50.0 	 1.3e
OPG Rx Rag/  IL2/ CD4 T Cells 14 2 84.6 	 10.2f 58.8 	 4.2f
a No significant differences between any 4 week group.
b (F) p  0.005, (T) p  0.001 compared with 7w IL2/.
c (F&T) p  0.001 compared with 9w IL2/.
d (F) p  0.0013, (T) p  0.017 compared with Rag1/  IL2/ T cells and (F) p  0.01, (T) p  0.03 compared with control animals.
e (F&T) p  0.001 compared to 7w IL2/, (F) p  0.026 (T) p  0.005 compared to 7w IL2/ mice.
f (F) p  0.046 (T) p  0.001 compared to Rag1/. (F) p  0.004, (T) p  0.001 compared to Rag1/  IL2/ T cells.
(femur p  0.001, Figure 2B; tibia p  0.001, not shown) control mice at 4, 7, and 9 weeks of age revealed that
RANKL/OPG (Figures 3A and 3B) and RANK (data notwere seen in IL2/ T cell inoculated Rag1/ chimeras
compared with IL2/T cell inoculated Rag1/ chimeras shown) mRNA levels were upregulated. Surprisingly,
OPG mRNA levels displayed the most dramatic in-and mock inoculated Rag1/ mice. By comparison,
C57BL/6-Rag1/ control mice had a bone volume and creases at 7 weeks of age. RANKL/RANK levels were
elevated to a lesser degree but were consistently higherBMD not significantly different from C57BL/6-Rag1/
IL2/ T cell chimeras (Figure 2B and Table 1). Histologi- in IL2/ mice at 4 and 7 weeks of age compared to
IL2/ or IL2/ littermates. The analysis of serum RANKL/cally, Rag1/ mice inoculated with IL2/ T cells exhib-
ited loss of trabecular bone below the growth plates OPG protein levels essentially confirmed mRNA analysis
(Figures 3C and 3D). Significant elevations in serum lev-and epiphyses and loss of cortical bone in both the
femur and tibia similar to that of IL2/ mice (Figures els of both RANKL (p  0.007) and OPG (p  0.014)
were evident in IL2/ mice compared to IL2/ mice.1A and 1B and data not shown). Osteoclast numbers
were significantly increased in IL2/ T cell Rag1/ chi- In contrast, serum levels of RANKL and OPG in IL2/
mice and IL2/ littermates were equivalent (data notmeras compared to Rag1/ control mice (Femur p 
0.017, Figure 2C, tibia p  0.008, not shown) and IL2/ shown). Serum OPG levels continued to rise in 9-week-
old IL2/ mice in contrast to levels of RANKL that hadT cell Rag1/ chimeras (Femur p 0.004, tibia p0.010,
data not shown). There were no significant differences returned to levels comparable to those seen in wild-
type mice. Increased OPG mRNA and protein levelsbetween Rag1/ control mice and IL2/ T cell Rag1/
chimeras. Collectively, these data demonstrate that acti- may represent a continuing homeostatic response, at-
tempting to reverse established osteopenia and RANKLvated T cells in IL2/ mice directly cause osteopenia
in vivo, which is associated with increased osteoclast driven osteoclastogenesis, thus maintaining a normal
bone mass. An important caveat in the interpretation ofnumbers. The increase in osteoclast numbers, the ele-
vated levels of OPG in IL2/T cell Rag1/ chimeras (p serum OPG levels is that the binding OPG to other fac-
tors such as TRAIL (Shipman and Croucher, 2003) and0.022, Figure 2D), together with differences in RANKL
serum levels in IL2/ T cell inoculated Rag1/ mice the presence of soluble RANKL can influence OPG de-
tection. The rise in serum OPG did however correlatesuggested that abnormalities in RANK/RANKL activity
might be a causal factor in bone loss in IL2/ mice, a with the decline in osteoclast numbers in IL2/ mice
by 9 weeks of age below those found in control micepossibility that was investigated further.
(Figure 1E). A similar increase in serum levels of OPG
was found in Rag1/ mice transfused with IL2/ T cellsIL2/ T Cells Influence Bone Metabolism as a Result
compared to groups of mock transfused animals or ani-of Excessive RANKL Production
mals transfused with IL2/T cells (p0.022, Figure 2D).The possibility that activated T cells influence bone me-
There was also a trend toward raised levels of RANKL intabolism through RANKL and OPG was investigated by
Rag1/ mice transfused with IL2/ T cells (76 pg/ml)comparing levels of RANK, RANKL, and OPG mRNA
over those with either IL2/ T cells inoculated (44 pg/ml)and/or protein in IL2/ and control mice. The compara-
or mock inoculated littermates (27 pg/ml) although thesetive analysis of mRNA expression by quantitative RT-
PCR in bone marrow mononuclear cells from IL2/ and differences did not reach significance. T cells were iden-
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Figure 2. Bone Loss in IL2/ Mice Is CD4 T Cell Mediated
Groups of Rag1/ mice were inoculated with either PBS (control) or CD4 T cells from IL2/ (/ T cells) or IL2/ (/ T cells) mice, and
6–8 weeks later tibia and femora were evaluated for bone density (A), trabecular bone area (B), and osteoclast numbers (C) as described in
legend of Figure 1. Serum levels of OPG (D) were analyzed by ELISA. The results shown are representative of those obtained from more than
five mice of each genotype (n/s  nonsignificant).
tified as a source of RANKL by antibody staining and ing colitis, splenomegaly, lymphadenopathy, and ane-
mia. Fc-OPG treatment halted and reversed bone dis-flow cytometric analysis of bone marrow mononuclear
cells of 7-week-old IL2/ and IL2/ littermate control ease, resulting in significantly increased bone density,
increased trabecular bone, and absence of osteoclastsmice (Figure 4A). IL2/ CD4 T cells expressed no or
very little RANKL. By contrast, virtually all CD4 T cells in treated IL2/ mice compared to nontreated IL2/
and IL2/ littermates (Table 1; Figure 5B; data notin the bone marrow of IL2/ mice express high levels
of RANKL. shown). A similar Fc-OPG-mediated reversal of osteope-
nia (Table 1) and total absence of osteoclasts (data not
shown) was seen in C57BL/6 Rag-1/ mice transfusedFc-OPG Reverses Bone Loss and Reduces
with IL2/ T cells after receiving the same regimen ofT Cell-Mediated Colonic Inflammation
OPG treatment. The effect of Fc-OPG on bone loss inIn an attempt to prevent or reverse bone loss and inflam-
these mice was not at the level of production of RANKLmation in IL2/ mice, animals were treated on alternate
by CD4 T cells since RANKL levels, as assessed by flowdays with recombinant Fc-OPG between 4 and 7 weeks
cytometry, were not significantly different on CD4 T cellsof age, after which both bone and colon histology were
in OPG-treated mice compared to those seen in non-examined. The dosing regimen used was based on pre-
treated IL2/ animals (data not shown).vious experience with mouse models using a chimeric
Fc-OPG also had a beneficial effect on intestinal in-human Fc-OPG protein. In earlier studies, antibodies to
flammation and the development of colitis in IL2/mice.Fc-OPG appeared in mouse serum around day 12 of
Histological analysis of the colon obtained from 7-week-dosing and were associated with a dose-dependent
old IL2/ control (Figures 5C and 5D), Fc-OPG treatedclearance of Fc-OPG and loss of pharmacology. The
IL2/ (Figures 5G and 5H), and nontreated IL2/ micerelatively high dose chosen for these experiments was
(Figures 5E and 5F), demonstrated an overall preserva-selected therefore to be well tolerated and to maintain
tion of tissue architecture and organization in Fc-OPGmaximal antiresorptive activity over the period of the
treated animals. Compared to nontreated IL2/ mice,study (C.R.D., unpublished data). Treated animals were
there was a reduction in T cell infiltration, reduced inci-also evaluated for the effects of Fc-OPG on other T cell-
mediated immunopathology seen in IL2/ mice, includ- dence of crypt hyperplasia, and an increased number
Immunity
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Figure 3. Aberrant Regulation of RANK/RANKL/OPG Production in IL2/ Mice
The levels of RANKL and OPG mRNA in bone marrow mononuclear cells of IL2/ (/), IL2/ (/), and IL2/ (/) mice at 4, 7, and 9
weeks of age was determined by quantitative (Real Time) PCR (A and B). Compared to IL2/ animals the level of RANKL mRNA in IL2/
bone marrow is approximately 2-fold higher at 4 and 7 weeks of age whereas OPG levels are between 2- and 4-fold higher at 4–7 weeks of
age. Serum levels of RANKL and OPG were determined by ELISA (C and D). Significant increases in the levels of OPG (p  0.014) at 9 weeks
and RANKL at 4 (p  0.003) and 7 weeks (p  0.007) of age were demonstrated in IL2/ mice when compared to IL2/ littermates.
of goblet cells in Fc-OPG-treated IL2/ mice. Fc-OPG creased numbers of CD11c DC compared to IL2/
littermates, the majority of which were mature, activatedtreatment did not however completely return the colonic
mucosa to that seen in 4-week-old IL2/ mice prior to, DCs as determined by high levels of MHC class II expres-
sion (Figure 6A) and costimulatory molecules CD80 andor coincident with, the onset of colitis (Figures 5A and
5B). To identify mechanisms of action of Fc-OPG, a CD86 (data not shown). Fc-OPG treatment of IL2/mice
effectively ablated colonic DC, reducing numbers to be-comparative analysis of colonic lamina propria mono-
nuclear cells was carried out in treated and nontreated low that seen IL2/mice (Figure 6A). That Fc-OPG might
act directly on colonic DC was suggested by the findingIL2/ mice. Flow cytometric analysis of lamina propria
cells demonstrated slight changes in the activation phe- that virtually all colonic DCs uniformly expressed low
levels of RANK (Figure 4B).notype of CD4 T cells, identified by expression of activa-
tion-associated antigens (CD69, CD95, CD45RB), in The antiinflammatory effects of Fc-OPG treatment ap-
peared to be local and restricted to the colon as thereOPG-treated animals compared to that of nontreated
animals. CD4 T cells in Fc-OPG treated animals had were no beneficial effects on other tissue pathologies
and inflammation. There was no demonstrable effect onlower levels of Fas and CD69 expression compared to
CD4 T cells in nontreated IL2/ mice (Figure 6B). Co- splenomegaly, anemia, or abnormal myelopoiesis seen
in IL2/ mice (data not shown) and the elevated levelslonic macrophage (CD204) numbers in Fc-OPG treated
animals were unchanged when compared to untreated of inflammatory cytokines (monocyte chemoattractant
protein-1 [MCP-1]), Interleukin-6 (IL-6), tumour necrosiscontrols (Figure 6A). There was however a change in
MHC class II expression levels in treated and nontreated factor- (TNF-), and Interferon-
 (IFN-
) present in the
serum of IL2/ mice compared to IL2/ littermatesanimals with colonic lamina propria macrophages in Fc-
OPG treated animals expressing lower levels of I-Ab. were not significantly reduced by Fc-OPG treatment
(Figure 6C).More striking differences were seen in colonic DC in
IL2/ mice compared to IL2/ and Fc-OPG treated Our findings therefore suggest that increased levels
of RANKL expression by CD4 T cells in IL2/ mice,IL2/ mice (Figure 6A). Nontreated IL2/ mice had in-
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Figure 4. RANKL and RANK Expression in
the Bone Marrow and Colon
(A) RANKL expression by CD4 T cells of
7-week-old IL2/ and IL2/ mice was de-
tected using a RANKL antisera and alexa-
flour-488 labeled secondary antibody. The
histograms represent the level of staining of
CD4 T cells by RANKL antibodies (filled in
profiles), or RANKL antibodies preincubated
with the peptides of RANKL used to generate
the RANKL antisera (solid lines, open pro-
files).
(B) RANK expression by colonic DC of 7-week-
old IL2/ mice was detected by staining co-
lonic lamina propria cells with antibodies to
CD11c and RANK (left-hand panel), or iso-
type-matched control antibodies (right-hand
panel).
acting via RANK, normally upregulates and supports RANKL/OPG system may therefore play a dual role in
these diseases, influencing not only the bone but alsoboth the survival and APC activity of colonic DC, provid-
gut pathology.ing a means of activating CD4 T cells, thereby increasing
The RANK/RANKL/OPG system is now established asthe inflammatory process and colitis. The results of Fc-
having a central role in both the regulation of normalOPG treatment are consistent with Fc-OPG having a
bone turnover and pathological bone disease. Our de-potent antiinflammatory effect that is restricted to the
scription of T cell-driven bone loss mediated via RANKLcolon and that by reducing DC survival it thereby elimi-
is consistent with, and confirms, findings of groups us-nates the APC for disease promoting colonic CD4
ing other animal models of bone disease (Kong et al.,T cells.
1999b). The significance of increased expression of
RANKL by both synovial fibroblasts and T cells and
Discussion bone destruction in patients with rheumatoid arthritis
(Udagawa et al., 2002) is also increased by our findings.
In this study we have described T cell-mediated bone A significant body of work has demonstrated that acti-
disease that develops in IL2/ mice, and in addition vated CD4 and CD8 T cells deregulate bone turnover
have identified both its cause and a treatment that re- due to their expression of RANKL (Weitzmann et al.,
verses osteopenia and is effective in treating colitis. Our 2001). T cells also drive osteoclast formation, can influ-
studies have shown that bone disease is caused by ence osteoblast activity, and induce both joint and bone
accumulation in the bone of activated T cells producing destruction (Horwood et al., 1999; Kong et al., 1999a;
RANKL. This results in increased osteoclast numbers, Nosaka et al., 2002; Rifas et al., 2003). The disruption
and an initial increase but then significantly decreased of normal T cell homeostasis and lymphoproliferative-
bone formation resulting in abnormal bone homeostasis, like disorder that occurs in IL2/ mice further highlights
the effects of which are convincingly treated by adminis- the requirement to control T cell activation in order to
tering Fc-OPG. Our studies have also identified, for the regulate bone turnover.
first time, a role for the RANKL/RANK/OPG system in Bone disease in IL2/ mice could be a direct or indi-
regulating intestinal inflammation by modulation of co- rect consequence of IL2 deficiency. Although originally
lonic DCs. Contrary to earlier reports (Kong et al., 1999a) described as T cell growth factor, IL2 is now known to
we have shown that Fc-OPG prevents the development play a central role in the homeostatic control of T cell
of T cell-mediated inflammation and hence regulates activation and survival (Schimpl et al., 2002). The ab-
colitis in the IL2/ mouse. This finding is intriguing in sence of this cytokine in IL2/ mice leads to hyperacti-
light of reports of bone loss associated with inflamma- vation of CD4 T cells, which as shown in this study,
tory bowel disease (Kirchgatterer et al., 2002) and Celiac uniformly express high levels of RANKL. As a result of
disease (Fickling et al., 2001), the underlying mecha- their inability to undergo activation-induced cell death
(Zheng et al., 1998), activated T cells infiltrate and accu-nisms of which have not been identified. The RANK/
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Figure 5. Fc-OPG Treatment Reverses Bone
Loss and Modulates Colitis in IL2/ Mice
(A) Four-week-old IL2/ mice were treated
with Fc-OPG (5 mg/kg sc on alternate days)
in PBS (n  12) or PBS alone for 3 weeks. At
the end of the treatment period colons were
removed for histological analysis and femurs
and tibia evaluated for bone density as de-
scribed in legend of Figure 1. Note the main-
tenance of goblet cells and decreased inflam-
matory T cell infiltrate in Fc-OPG treated (G
and H) compared to nontreated 7-week- old
(E and F) IL2/ mice. Colon histology of
4-week-old IL2/ (A and B) and 7-week-old
IL2/ (C and D) mice are included for com-
parison. The heavy inflammatory cell infiltrate
(ICI) in colitic IL2/ mice (E) is highlighted by
arrowheads, as are goblet cells (GC) in wild-
type (D) and untreated (F) and treated (H)
IL2/ mice. Scale bars in (C), (E), and (G),
and (D), (F), and (H) represent 200 m and
300 m and those in (A) and (B) 400 m, re-
spectively.
(B) Assessment of BMD in OPG treated ani-
mals. Note that Fc-OPG treatment not only
corrects and significantly increases BMD in
the IL2/ mice (femur and tibia p  0.001)
but significantly increases mean BMD above
that seen in normal age matched IL2/ mice
(femur p  0.026; tibia p 0.005, not shown).
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Figure 6. Absence of Colonic Dendritic Cells in Fc-OPG Treated IL2/ Mice
Colonic lamina propria mononuclear cells from 7-week-old IL2/, IL2/, and Fc-OPG treated IL2/ mice were stained with antibodies specific
for DC (CD11c) (A upper panels), macrophages (CD204) (A lower panels), CD4 T cells, and activation associated antigens (MHC class II, CD69,
CD45RB, and CD95) (B). The values shown in quadrants of the dot plots represent the proportion of cells stained positive and the bar graphs
represent the proportion of CD4 T cells stained positive / SEM. The data shown are representative of that obtained from three independent
experiments. (C) The levels of representative inflammatory cytokines in the serum of 7-week-old IL2/, IL2/, IL2/, and IL2/ OPG treated
mice were determined by cytokine cytometric bead arrays (BD). Although IL2/ mice exhibit elevated levels of MCP-1, IL-6, TNF, and IFN
,
Fc-OPG treatment had no significant effect on the levels of any of these cytokines. The data shown are representative of that obtained from
a minimum of four mice.
mulate in peripheral tissues and in the bone marrow in  T cell-deficient IL2/ mice, is consistent with IL2
influencing bone turnover via effects on T cell activation.(Kramer et al., 1995; Reya et al., 1998), where they pro-
mote the generation and activation of osteoclasts and Our findings do not however exclude a more direct ac-
tion of IL2 on osteoclasts (or osteoblasts). To our knowl-influence osteoblast function. The ability to reproduce
bone disease in Rag1/ mice by adoptively transferring edge there are no published reports describing the ef-
fects of IL2 on the RANK/RANKL/OPG system. There areIL2/ splenic T cells, and the absence of bone disease
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however contradictory reports of IL2 influencing bone cannot be wholly reversed even with the high, but en-
turnover. Investigators have suggested that there is no dogenous, physiological levels of OPG seen in the IL2/
direct IL2 action on resorption (Gowen and Mundy, 1986; mouse and may require pharmacological levels ob-
Seymour et al., 1985) or osteoclast development (Ogata tained by exogenous administration to achieve a thera-
et al., 1999). However, evidence to the contrary also peutic effect. The recent finding that Peyers patch DC
exists with both IL2 (Ries et al., 1989; Schneider and express RANK and that treatment with RANK-Fc, which
Relfson, 1994) and soluble IL2R (Oelzner et al., 1999; also antagonizes the actions of RANKL, enhances the
Schultz et al., 1998) levels being associated with in- induction of tolerogenic immune responses (Williamson
creased bone resorption. Since there is no published et al., 2002), suggests that DCs in different regions of the
evidence suggesting the osteoclast either can or cannot intestinal tract respond differently to RANK-mediated
express IL2R, the direct involvement of the IL2/IL2R signals and promote different T cell responses. This
signaling pathway in osteoclast activation or develop- apparent divergence in function of DCs in the small
ment cannot be excluded. We have previously observed versus large intestine might be explained by differences
that myeloblasts and promyelocytes express the IL2R in the origin and precursor populations, or microenviro-
chain and that IL2 deficiency produces abnormal my- mental influences. These differences may influence the
eloid development in IL2/ mice (Reya et al., 1998). generation of tolerogenic versus activating DCs. Al-
Other investigators have also shown that IL2 increases though the central role of intestinal DCs in maintaining
the cytotoxicity and proliferation of monocytes (Es- immune homeostasis and their relationship to gut bacte-
pinoza-Delgado et al., 1995). It would not therefore be ria has only recently been highlighted (Stagg et al., 2003),
unreasonable to postulate that the formation and activa- it is worth noting that in contrast to small intestinal DCs
tion of osteoclasts, which are derived from macrophage/ very little is known about the origin, heterogeneity, and
monocyte precursors, may be influenced more directly function of colonic DC (Bell et al., 2001; Krajina et al.,
by IL2. These alternative mechanisms are worthy of fur- 2003).
ther investigation. Our findings have significant implications for the treat-
During treatment of bone disease in IL2/ mice it ment of human disease. The most interesting possibili-
became evident that the colitis normally observed in ties are presented by inflammatory conditions associ-
these mice between 7 and 9 weeks of age was both macro- ated with both bowel and bone complications such as
scopically and microscopically reduced. Increased num- ulcerative colitis, Crohns disease, and celiac disease
bers of RANK DC in the colon of IL2/ mice and their (Fickling et al., 2001; Klaus et al., 2002). Inflammatory
subsequent loss during Fc-OPG treatment suggests bowel disease presents a significant clinical problem
that RANK-RANKL interactions are required to sustain and can be associated with metabolic bone disease
DC survival and growth in the colon as demonstrated often present at diagnosis (Lamb et al., 2002) and not
in vitro with cultured, bone marrow derived, DCs (Ander- necessarily induced by steroids alone (de Jong et al.,
son et al., 1997; Josien et al., 1999, 2000; Wong et al., 2002). If therapeutic interventions were available to treat
1997). Our findings also identify colonic DC as being the both the osteopenia found in these conditions, along-
APC responsible for activating pathogenic T cells in the side reducing gut inflammation, then both improve-
IL2/ model of inflammatory bowel disease. Interest- ments in quality of life and reductions in complications
ingly this local antiinflammatory effect of OPG was not associated with these diseases could be achieved.
observed in the joints of a rat model of arthritis treated
with Fc-OPG (Kong et al., 1999a) and the effects we
Experimental Proceduresobserve have not been previously reported. There are
a number of possible explanations for these differing
Mice
results, including differences in species of animal model C57BL/6 wild-type, C57BL/6 IL2/, BALB/C IL2/, C57BL/6
and dosing regimens used. The experiments previously Rag1/, and C57BL/6 TCR/ were obtained from The Jackson
reported used a shorter dosing interval of 4 days of daily Laboratory and were used between 4 and 30 weeks of age. IL2/
mice were obtained from heterozygote mating and were identified1 mg/kg Fc-OPG in 8- to 9-week-old Lewis rats. Our
by PCR analysis of tail DNA samples (Schorle et al., 1991). The IL2results were obtained by a more sustained dosing regi-
mutation was bred onto the C57BL/6 TCR/ background strainmen over 21 days in 4-week-old C57BL/6 IL2/ mice
with IL2/  TCR/ progeny being identified by PCR analysis ofusing alternate day 5 mg/kg subcutaneous dosing. The
tail DNA and flow cytometric analysis of peripheral blood mononu-
underlying mechanisms involved in T cell-mediated in- clear cells stained with anti-CD4 and anti-TCR antibodies. IL2/
flammatory colitis and bone disease are also likely to and IL2/ littermates were used as control animals. All animals were
be significantly different. The characteristics of APC in bred and maintained in individual isolator cages at the University of
Leeds.the two organs almost certainly vary due to the differing
microenvironment, with DC-T cell interactions playing a
greater role in the priming of mucosal T cell responses Cell Isolation
in the gut, where they are already known to have a more Whole bone marrow was obtained from murine long bones by dis-
significant role than in the joint and bone marrow. The secting out and flushing femora and tibia with RPMI 1640 media. A
single cell suspension was obtained by gentle syringe agitation.antiinflammatory effects of Fc-OPG appear therefore to
Erythrocytes were then lysed with 0.86% ammonium chloride priorbe specific to, and restricted to, sites of inflammation
to washing and counting mononuclear cells. Lamina propria mono-where RANK DC are the major APC. Our finding that
nuclear cells were retrieved from 5 mm2 segments of colon mucosa
Fc-OPG at the doses used does not significantly affect by digestion for 2 hr in collagenase IV (1.5 mg/ml, Sigma) at 37C
circulating inflammatory cytokine levels nor the pathol- under gentle agitation. Dendritic cells and macrophages were en-
ogy in other tissues supports this hypothesis. Our results riched from the resultant cell suspension by collecting the 43/63%
Percoll density gradient (Amersham) after a 30 min centrifugationalso suggest that the actions of RANKL in this setting
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at 200 g. T cells were collected after separation on a 60% Percoll X-ray system (Hewlett Packard, McMinnville, OR). Total bone min-
eral density (BMD) of the femur and tibia were measured by dual-density gradient.
energy X-ray absorptiometry (DXA) using a PIXImus scanner (Lunar,
Madison, WI) with dedicated small animal software. Specific areasAntibodies and Flow Cytometric Analysis
To prevent nonspecific antibody binding cells were incubated for of interest adjacent the distal femoral growth plate and the proximal
tibial growth plate were also assessed.20 min at 4C with 5% rat serum and 10 g/ml mouse Ig (Sigma-
Aldrich, Poole, UK). For all staining experiments, isotype-matched
antibodies of relevant specificity were used to determine the level RANK/RANKL/OPG mRNA Analysis
of nonspecific staining and frequency of cells stained with test anti- Expression of mRNA encoding OPG, RANKL, and RANK in whole
bodies. Cells were stained with fluorochrome and/or biotin conju- bone marrow mononuclear cells was assessed using Taqman RT-
gated antibodies to CD45(YW62.3), CD3(CT-CD3), MAC1(M1/70.15), PCR (ABI PRISM 7700 Sequence detection system, Applied Biosys-
CD40(3/23), CD54(3E2), CD4(CT-CD4), I-AI/E(M5/114.15.2), CD80 tems, Cheshire, UK). All specific primer probe sets were optimized
(RMMP-1), CD86(RMMP-2), CD69(H1.2F3), CD45RB(16A), pur- and tested for use using the comparative Ct method (ABI user bulle-
chased from TCS Biologicals (Towcester, UK), alongside CD95(13), tin #2, ABI Prism 7700 sequence detection system), Abl being used
purchased from Becton Dickinson (Franklin Lakes, NJ, USA). Stain- as a control gene.
ing for RANK was performed using rat anti-mouse RANK in combina- RANK: Sense, GGTCTGCAGCTCTTCCATGAC; Antisense, TGAGA
tion with F(ab)2 goat anti-rat IgG (Serotec, Kidlington, Oxford, UK) CTGGGCAGGTAAGCC; Probe, CTGAGGAGACCACCCAAGGAG
with appropriate controls. For intracellular staining and detection GCC-FAM.
of cytoplasmic RANKL cells were first stained with antibodies to RANK LIGAND: Sense, TTGCACACCTCACCATCAATG; Anti-
cell surface antigens. Cells were then fixed, permeabilized, and sense, TTAGAGATCTTGGCCCAGCCT;
stained with a goat anti-RANKL antisera (Santa Cruz Biotechnolog- Probe, TGCCAGCATCCCATCGGGTTCC- FAM.
ies, Santa Cruz, CA, USA) followed by donkey anti-goat Ig-Alexafluor OPG: Sense, CTCTGTGAAAGCAGCGTGCA; Antisense, GGCTCT
488 (Alexis Corp, Notts, UK). As a control, aliquots of anti-RANKL CCATCAAGGCAAGA; Probe, ATCTCGGCCACTCGAACCTCAC
antisera were preincubated with the RANKL peptide used to gener- CAC-FAM.
ate the antisera. All antibody stained cells were analyzed on a FACS ABL: Sense, TGGAGATAACACTCTCAGCATCACTAAAGG; Anti-
Caliber cytometer (Becton Dickinson) using Cell Quest software sense, GATGTAGTTGCTTGGGACCCA;
(Becton Dickinson). All viable cells, as determined by light scatter Probe, CCATTTTTCGTTTGGGCTTCACACCATT FAM.
properties or exclusion of vital dyes such as propidium iodide
were analyzed. Serum Analysis
RANKL and OPG protein levels were measured, in serum obtained
Histological and Histochemical Analysis by cardiac puncture, using commercial ELISA kits (R&D Systems,
Femora and tibiae from IL2/, IL2/, and IL2/mice were analyzed Abingdon, UK) according to the manufacturer’s instructions. Serum
at 4, 7, and 9 weeks of age. These time points had been established bone-specific alkaline phosphatase levels were measured using
from previous work to correspond to negligible, moderate, and se- Labmedics ALP DEA kit on a Labmedics Konelab 30i (Labmedics,
vere clinical disease. All bone samples were decalcified in EDTA Manchester, UK). Serum samples were also taken from 7-week-old
prior to embedding in paraffin and sectioning. Three micron sections IL2/, IL2/, IL2/, and IL2/ OPG treated mice for assessment
were cut and stained with haematoxylin and eosin (H&E). Trabecular of inflammatory cytokine levels (IL6, IL10, IL12, MCP1, TNF, and
bone area as a proportion of the total bone area was determined IFN
) using flow cytometric cytokine bead arrays (Becton Dickinson)
in the femoral metaphysis and the proximal tibial metaphysis at two according to the manufacturer’s instructions.
section levels, in an area of 0.64 mm2 and 0.25 mm from the growth
plate, using Leica QWin image analysis system (Leica Microscope Adoptive T Cell Transfer Experiments
Systems, Milton Keynes, UK). Sections of the femora and tibia were Three groups (total n  16) of 6-week-old C57BL/6-Rag1/ mice
also stained for the presence of tartrate-resistant acid phosphatase were inoculated intraperitoneally with 6–9  106 splenic CD4 T cells
(TRAP) to identify osteoclasts and then counterstained with Gill in PBS (purity94%) obtained from C57BL/6 IL2/ or IL2/ animal
Haematoxylin. The number of osteoclasts in a 0.56 mm2 area 0.25 by negative immunomagnetic selection (StemCell Technologies,
mm from the growth plate were counted (number/mm2). Colonic Vancouver, BC, Canada), or with PBS alone. Treated animals were
tissues were processed by fixation in 10% formalin, prior to embed- maintained under conventional housing conditions until they dis-
ding in paraffin, sectioning, and staining with H&E.
played clinical signs of disease (6–8 weeks posttreatment) at which
time they were euthanized. Tibia and femora were analyzed using
Bone Dynamic Histomorphometry
radiographic, densitometric, histological, and histochemical meth-
IL2/, IL2/, and IL2/ mice at 4, 7, and 9 weeks of age were
ods as outlined above.
treated with 25 mg/kg tetracycline (Grunenthal, 52088 Aachen) by
subcutaneous injection. Six days later the mice were injected with
Fc-OPG Treatment20 mg/kg calcein green (Sigma, Poole, UK). Forty eight hours later
Recombinant Fc-OPG was administered to two different experimen-mice were euthanized, the femora and tibia removed, fixed in etha-
tal groups of animals (n  12). In the first experimental group, Fc-nol, and embedded in methyl-methacrylate resin. Ten micron sec-
OPG was given subcutaneously (5 mg/kg on alternate days) totions were cut and histomorphometric analysis performed using
4-week-old C57BL/6-IL2/ mice for a total of 3 weeks. Tibia andtransmitted and epiflourescent microscopy and a computer linked
femora were then processed for densitometric, histological, andanalyzer (Osteomeasure, Osteometrics, Atlanta, Georgia). Two non-
histochemical analyses. In addition, full blood counts were per-consecutive sections per animal were analyzed for each parameter
formed on peripheral blood samples. Colons were processed forin a blinded manner. A standard area of 0.72 mm2 (1.2 mm parallel
histochemical and immunochemical staining of sections and flowto cortex by 0.6 mm) was used, the distal border of which was
cytometric analyses of lamina propria mononuclear cells. In thesituated 0.25 mm above the growth plate to exclude the primary
second protocol, Fc-OPG was administered subcutaneously (5spongiosa. Trabecular width was derived from Osteomeasure. Min-
mg/kg on alternate days) to 6-week-old C57BL/6 Rag-1/ miceeral apposition rate (MAR) was determined by dividing the mean
immediately after transfusion with T cells from IL2/ or IL2/ micedistance between the tetracycline and calcein labels by the time
(see above). Tibia and femora were analyzed at 6–8 weeks posttreat-interval between the administration of the labels. The length of tra-
ment using radiographic, densitometric, histological, and histo-becular bone perimeter covered by double label was expressed
chemical methods.as a percentage of the total length of cancellous bone perimeter
(DLS/BS).
Statistical Analysis
All data was assessed for normal distribution using a Shapiro-WilkRadiographic and Bone Densitometric Analysis
test. For parametric data, analysis was performed using either Stu-Lumbar vertebrae, femora, and tibiae from IL2/ and control ani-
mals of various ages (see above) were radiographed using a Faxitron dent t test where only two data sets were compared or analysis of
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variance followed by a post-hoc Tukey test when more than two Horwood, N.J., Kartsogiannis, V., Quinn, J.M., Romas, E., Martin,
T.J., and Gillespie, M.T. (1999). Activated T lymphocytes supportdata sets were present. Nonparametric data was assessed using a
Mann-Whitney U test. Statistical significance was taken as p 0.05. osteoclast formation in vitro. Biochem. Biophys. Res. Commun.
265, 144–150.
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